Our business model allows us to pursue a broad range of cell and gene therapy product candidates in therapeutic areas of interest with high clinical and commercial potential.
At Cell BioEngines, we build a diverse portfolio of immune cell-based therapies originated within our team, through out-licensing from some of the world's largest academic institutions or partnerships with pharma-biotech companies.
We are an innovative cellular medicine company focussed on generating meaningful value creation opportunities through our diversified pipeline with the potential to produce life-changing therapies for people in need.
To democratize cellular medicine, we leverage our significant platform technology expertise to expand our product portfolio spanning several large market therapeutic areas. Our diversified product pipeline includes both, pre-clinical and clinical-stage candidates.